GLOW blend
Not FDA approvedUnapproved multi-peptide blend
Also known as: GLOW peptide
Very thin human evidence
- Regulatory standing. Sold as a research chemical, not approved
- Anecdotal. Community reports, no controlled data
- No registered human trials. Nothing registered on ClinicalTrials.gov
- No sources. Nothing cited to verify
Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.
What it is
GLOW is a marketed blend combining three separate peptides: GHK-Cu, a copper-binding tripeptide studied mainly for skin and wound effects, BPC-157, a synthetic fragment derived from a stomach protein, and TB-500, a synthetic peptide based on a region of thymosin beta-4. Each component is thought to influence tissue repair pathways such as collagen formation, blood vessel growth, or cell migration, and the blend is promoted on the idea that these effects combine.
What the evidence shows
The blend itself is not FDA-approved and no registered human trials or published studies of this specific combination were identified. Evidence for the individual components is mostly animal and lab work, with only limited human data for topical GHK-Cu, so any combined benefit is unproven.
What is in this blend
A blend is scored on its own, but the evidence for each ingredient lives on its own profile. Mixing compounds adds unknowns that none of the individual studies cover.
Sources
Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.